ALK-Positive Anaplastic Large Cell Lymphoma Clinical Trial
Official title:
Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL)
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory ALK-positive Anaplastic Large Cell Lymphoma.
This is a prospective, open-label, one-arm, multicenter clinical trial, aimed to evaluate the safety, tolerability, and efficacy of crizotinib combined with etoposide followed by autologous hematopoietic stem cell transplantation for relapsed and refractory ALK-positive ALCL. A total of 20 patients are planned to be enrolled into the study. Patients with diagnosis of relapsed and refractory ALK-positive ALCL will be treated with crizotinib plus etoposide capsules followed by autologous hematopoietic stem cell transplantation. The primary end points are objective responder rate (ORR) and progression free survival(PFS) and the secondary end points include overall survival(OS) , and adverse events. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04796857 -
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04476459 -
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05934045 -
Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
|
||
| Recruiting |
NCT04058470 -
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03493451 -
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
|
Phase 2 |